Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
FaviƩ, Laurent Ma Murk, Jean-Luc Meijer, Adam Nijstad, A Laura van Maarseveen, Erik M Sikma, Maaike A
FaviƩ, Laurent Ma
Murk, Jean-Luc
Meijer, Adam
Nijstad, A Laura
van Maarseveen, Erik M
Sikma, Maaike A
Citations
Altmetric:
Series / Report no.
Open Access
Type
Article
Language
en
Date of publication
2017-11-29
Year of publication
Research Projects
Organizational Units
Journal Issue
Title
Pharmacokinetics of favipiravir during continuous venovenous haemofiltration in a critically ill patient with influenza.
Translated Title
Published in
Antivir Ther 2018; 23(5):457-61
Abstract
Favipiravir is a novel antiviral drug approved for influenza treatment in Japan. Little is known about favipiravir pharmacokinetics in critically ill patients. Here, we report a patient with influenza treated with favipiravir and undergoing continuous venovenous hemofiltration (CVVH) on the Intensive Care Unit of a tertiary hospital in the Netherlands. Pharmacokinetic analyses showed increased clearance and decreased plasma levels compared to healthy volunteers. CVVH has no clinically relevant contribution to total clearance. Despite susceptibility to favipiravir, the influenza virus was not cleared. A multi-disciplinary approach is needed to ensure optimal favipiravir treatment in critically ill patients.